tebu-bio’s latest Travel Grant draw took place on June 16th, and saw six more researchers win 400 Euros each towards attending the meeting of their choice.

Here’s some news from two of our previous winners (in October 2016 and February 2017), who were happy to share these pictures from the same meeting they both attended!

27th European Congress of Clinical Microbiology and Infectious Diseases – Vienna, Austria –  April 2017

Dr Giuliana Banche of the University of Torino (Italy) presenting her research.

Beatriz Rojo of the CIBIR (Spain), presenting her research.

Interested in winning 400 euros for your next meeting?

tebu-bio’s fourth and final draw for 2017 will take place in October, applications are now open and can be uploaded online here.

Galectin-3 (Mac-2) is a β-galactoside-binding lectin expressed in a variety of tissues and cell types (incl. activated macrophages, eosinophils, mast cells, dendritic cells, kidney cells, and sensory neurons).
Galectin-3 is a promiscuous protein modulating a diverse set of cellular functions such as cell adhesion, cell-matrix interactions, cell migration, macrophage activation, and apoptosis. [Read more…]

Neutralizing MAb Anti-Human Interferon Lambda Receptor 1, Clone MMHLR-1 – PBL Assay Sciences at tebu-bio

PBL Assay Sciences offer a new monoclonal antibody to neutralize Human Interferon (IFN) activity, the Anti-Human Interferon Lambda Receptor 1, Clone MMHLR-1 (MAb).

This antibody is suitable for use in Type III IFN neutralization, flow cytometry, immunohistochemistry and immunoprecipitation. It neutralizes biological activity of human Type III IFNs (IFN lambda 1, 2 & 3, i.e. IL-29, IL-28A & IL-28B, respectively) at the Lambda Receptor 1 (i.e. IL-28 Receptor 1), and blocks Type I interferon receptor complex.

This complements the existing offer of antibodies and proteins to neutralize human and mouse IFN activities, available across Europe through tebu-bio’s network of local offices.

This slideshow requires JavaScript.